GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines.
Genistein combined polysaccharide (GCP), derived from soy bean extract, is comprised of deglycosylated isoflavones, such as genistein and daidzein. The goal of this work was to determine if GCP is effective in lymphoid cancers. In three human and four canine lymphoid cell lines, GCP inhibited proliferation and induced G2/M arrest. Additionally, increased apoptosis was observed in Ramos and Jurkat lines. These results demonstrate that GCP is effective in lymphoid cell lines of both human and canine origin. Due to its minimal toxicities, increased bioavailability, and in vitro efficacy, GCP may have clinical utility in the treatment of patients with lymphoma.
McCall
Jamie L
JL
Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, Sacramento, CA 95817, USA.
Burich
Rebekah A
RA
Mack
Philip C
PC
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004249:DNA Damage; D004285:Dogs; D005434:Flow Cytometry; D019833:Genistein / Q000494:pharmacology*; D006801:Humans; D020287:In Situ Nick-End Labeling; D008223:Lymphoma / Q000473:pathology*; D011134:Polysaccharides / Q000494:pharmacology*
D011134:Polysaccharides; C473311:genistein combined polysaccharide; D019833:Genistein